ThromboGenics : becomes “Oxurion”

Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders

Leuven, Belgium. ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing innovative treatments for back of the eye disorders, and with an innovative pipeline in diabetic eye disease, announces that all name change resolutions proposed at an Extraordinary General Meeting ('EGM') held today Monday September 3, 2018, gained shareholder approval. As a result, ThromboGenics NV will become 'Oxurion NV'.

The name change will be implemented in the next days and weeks. The Company stock ticker symbol will also change from 'THR' to 'OXUR'.

The new corporate website will be www.oxurion.com.

Patrik De Haes, MD, CEO of ThromboGenics, comments: 'The new name, Oxurion, is designed to better reflect ourambition to deliver best in class therapies for back of the eye disorders. The renaming comes at a moment when we have delivered important clinical milestones and are accelerating the development of our unique pipeline of disease modifying compounds for diabetic eye disease. Moreover, we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.'

'The new Oxurion logo, combined with the tagline 'Advancing science. Enhancing vision.'has been designed to convey the company's technological and scientific core, by linking our current strength and vision with our exciting future ambition.', he concludes.